Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)a is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein-protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBPa in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBPa possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBPa protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBPa inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBPa.
Introduction
C/enhancer binding protein (EBP)a belongs to a family of transcription factors that homo-and hetero-dimerize via their conserved C-terminal leucine zipper domains and bind DNA as dimers through the adjacent basic regions (b-Zip) (Landschulz et al., 1989) . C/EBPa and PU.1 are two major regulators of hematopoietic stem cell development. Unlike PU.1, which governs transcription of a wide spectrum of myeloid-specific genes, C/EBPa has a more specific function in granulopoietic stem cell development (Scott et al., 1992; Muller et al., 1995) . C/EBPa À/À knockout mice show no mature granulocytes, whereas other hematopoietic lineages are not affected (Zhang et al., 1997) . Recent findings have demonstrated a direct link between myeloid leukemogenesis and certain transcription factors including C/EBPa.
Mutations in C/EBPa leading to its disruption have recently been shown in acute myeloid leukemia (AML) (Pabst et al., 2001b; Gombart et al., 2002; Frohling et al., 2004; Perrotti et al., 2004) . In a recent study, Smith et al. (2004) have shown a C/EBPa mutation in inherited AML, where multiple members were affected by AML associated with an identical mutation in CEBPA. Several studies have emphasized that proteinprotein interactions of transcription factors may contribute to leukemogenesis (Westendorf et al., 1998; Pabst et al., 2001a; Reddy et al., 2002; Tenen, 2003; Vangala et al., 2003) . Modified properties of a multiprotein complex resulting from variable interacting partners are likely to be involved with all three hematopoietic checkpoints: cell proliferation, differentiation and apoptosis; impairment of each of which may induce leukemia. Hence, an important emerging concept is that not only relative expression of transcription factors is important, but that protein-protein interactions among various transcription factors are crucial (Sieweke and Graf, 1998) . Potential antagonistic protein interactions leading to a block in C/EBPa function in AML have been well implicated in recent findings (Pabst et al., 2001a; Vangala et al., 2003; Zheng et al., 2004) . Interestingly, C/EBPa also functions via direct proteinprotein interactions in normal stem cell development (Behre et al., 2002a; D'Alo et al., 2003; Muller et al., 2004) ; PU.1 and c-Jun inactivation (Rangatia et al., 2002; Reddy et al., 2002) , E2F repression (Porse et al., 2001) , and cdk2 and cdk4 inhibition (Wang et al., 2001 ) by C/EBPa are all accompanied by direct protein-protein interactions. Moreover, different protein partners of C/EBPa in young and old mice livers itself demonstrate the importance of protein-protein interactions during ageing (Iakova et al., 2003) .
Owing to its role in differentiation, anti-proliferation and apoptosis, functional inactivation of C/EBPa is central to the pathogenesis of AML. However, molecular mechanisms behind this are poorly understood except for some cases (Pabst et al., 2001b; Perrotti et al., 2002; Zheng et al., 2004) . Recent advances in mass spectrometry have revolutionized the analysis of the proteome of a cell by simplifying the analytical protocol and increasing the sensitivity of detection by several orders of magnitude. Global high throughput mass spectrometry-based functional proteomic approaches could lead to new insights into the network of C/ EBPa-interacting proteins relevant for stem cell development and AML therapeutics (Mann et al., 2001; Cristea et al., 2004; Balkhi et al., 2006) . Therefore, to evaluate the significance and role of proteins interacting with C/EBPa and modulating its activity, we analysed the C/EBPa multiprotein complex using mass spectrometry-based proteomics.
Results

Proteomic identification of the C/EBP-DBD multiprotein complex by 2D gel electrophoresis
In order to identify co-activator proteins interacting with C/EBPa and modulating its activity in stem cell development and AML, a mass spectrometry-based proteomics approach was applied. The DBD of C/EBPs contains a conserved leucine zipper region, which is necessary for interaction with other proteins; therefore, we used glutathione-S-transferase (GST) fused with DBD to identify C/EBP-interacting proteins. Figure 1a depicts wild-type C/EBPa with conserved domains of C/EBP family proteins and GST-fused constructs, which we used for our investigation in this study. We purified GST fusion proteins from bacterial strain Escherichia coli after inducing with 0.5 mM isopropyl-thiogalactopyranoside (IPTG). The commassie-stained gel picture shows expression of GST fused with DNA-binding domain (DBD) of C/EBP (GST-DBD), GST-C/EBPa and GST alone ( Figure 1b) ; Different amount of commercially available bovine serum albumin was resolved together to quantify the respective volume of GST fusion proteins to be used in further assays. We confirmed the physical activity of bacterially purified fusion proteins by assessing their interaction with in vitro-translated (ivt PU.1) and endogenous PU.1 from U937 nuclear extract (NE); PU.1 is known to interact with C/EBPa in its DBD (Reddy et al., 2002) (Figure 1c-d) . Next, we performed GST pull down assay from NE of myelomonocytic cell line U937. Proteins from NE bound with fusion proteins on GST sepharose beads were lysed in sample buffer and subsequently separated by isoelectric focussing (IEF) in first dimension followed by second-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Silver staining was performed to visualize differentially interacting proteins from 2D gels (Figure 1e) . Protein spots present only in GST-DBD gel were excised and analysed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry for further identification; as control we identified GST as a common spot from both gels. Identified protein spots interacting with the DBD region of C/EBP are listed in Figure 1f . Note that for large number of protein spots the mowse score was insignificant and hence could not be identified. This is presumably due to small spot size (protein amount), silver interference and low sensitivity of mass spectrometer.
C/EBPa physically interacts with JNK1 in vitro and in vivo c-Jun N-terminal kinase (JNK) is an important member of mitogen-activated protein kinase (MAPK) family and regulates the activity of its physically associated substrates (Fuchs et al., 1997) . Therefore, we chose JNK to study the biological relevance of its interaction with C/EBPa. We confirmed direct protein-protein interaction between GST-DBD and JNK1 by incubating GST-DBD with methionine-labelled ivt JNK1 for 90 min. After stringent washing, interaction between JNK1 and GST-DBD was observed (Figure 2a ; lane 5). We next examined whether JNK1 interacts with full-length C/EBPa and performed GST pull down assay using GST-DBD, GST-C/EBPa and GST alone from 25 ng/ml anisomycin-induced (U937 radioimmunoprecipitation assay (RIPA*) and uninduced (U937 RIPA) cell lysates; anisomycin is a potent activator of JNK which acts on upstream activators of JNK (Bogoyevitch et al., 1995; Morton et al., 2003) . Immunoblot against JNK1 showed direct interaction of JNK1 (Figure 2b ; lanes 2, 6 and 8 with fast migrating lanes) and phospho-JNK1 (pJNK) (Figure 2b ; lanes 1, 5 and 7 with slow migrating bands as compared to respective uninduced conditions) with GST-DBD and GST-C/EBPa. The higher binding affinity of GST-C/ EBPa with JNK could be owing to favorable conformation of full-length wild-type C/EBPa protein as compared to shorter GST-DBD; GST-c-Jun served as positive control (Figure 2b ). Note that, bands below 35 kDa, GST or degraded GST-fusion proteins show input in each lane. We also examined in vivo interaction of C/EBPa and JNK1 by co-immunoprecipitation of JNK1 from U937 RIPA lysates. Immunoblot against JNK1 (upper panel) followed by C/EBPa (lower panel) after stripping the same membrane confirmed in vivo interaction of JNK1 and C/EBPa in myeloid cells ( Figure 2c ).
As JNK interacts with GST-DBD, we wished to map down the region of C/EBPa interacting with JNK1 using previously reported C/EBP-DBD mutants (Landschulz et al., 1989) . 293T cells were transfected with different C/EBP-DBD mutants described in Materials and methods together with hemagglutinin (HA)-JNK; 24 h post-transfection RIPA extracts were prepared and JNK was immunoprecipitated using HA antibody. Immunoblot against HA and subsequently with C/EBPa antibody after stripping the same membrane shows JNK interaction with C/EBPa and various DBD mutants with variable intensity (Figure 2d ). Taken together, this confirms that JNK1 directly interacts with DBD region of C/EBPa. Further studies using C/EBPa basic region deletion mutant could further narrow down the region of C/EBPa interacting with JNK1. Commassie-stained gel shows bacterially purified GST-C/EBPa, GST-DBD and GST proteins; different amounts of commercially available purified bovine serum albumin was separated together to compare the equivalent amount of bacterially purified proteins. (c, d) Immunoblot against PU.1 antibody after GST pull down of PU.1 from ivt PU.1 and U937 NE shows interaction with GST-DBD; sepharose beads served as control. (e) Silver-stained 2D gel shows differentially expressed proteins after GST pull down from NE of U937; proteins excised and subsequently analysed by mass spectrometry are marked with arrow. (f) List of the 2D-gel separated C/EBP-DBD multiprotein complex identified by MASCOT search; protein scores greater than 62 are significant.
Active JNK increases C/EBPa protein stability by inhibiting its ubiquitination JNK1 regulates ubiquitination and hence protein stability of its physically associated substrates (Fuchs et al., 1997) . Considering that C/EBPa levels are controlled post-translationally (Hattori et al., 2003; Subramanian et al., 2003) , we determined the effect of JNK1 on the stability of former protein. Induced activation of JNK in acute promyelocytic NB4 cells with 25 ng/ml anisomycin significantly increased the expression of C/EBPa (Figure 3a .i, ivt C/EBPa-His, 46 kDa used as positive control; upper panel, lane 6) which is consistent with JNK activation as shown by phospho-c-Jun expression in a separate immunoblot of same lysates after indicated time points (3a.ii). A similar effect was observed with acute myelomonocytic HL60 cells when treated with 25 ng/ml of anisomycin ( Figure 3b) ; 25 ng/ml anisomycin significantly activates JNK1 in HL60 cells (Terrance A Stadheim, 2002) . We also assessed C/EBPa-inducible cell line K562C/EBPa-ER for JNK-induced C/EBPa protein stabilization, where C/EBPa-ER protein is active only when induced with 1 mM b-estradiol but with accelerated degradation (Cleaves et al., 2004) . Immunoblot against C/EBPa shows anisomycin induction together with b-estradiol can reduce the degradation of C/EBPa-ER (Figure 3c ). Additionally, MEKK1 (an upstream member of MAPK pathway that binds to JNK and thereby facilitates the receipt of signals from upstream inputs to activate it (Xu and Cobb, 1997) ), with or without C/EBPa was expressed in C/EBPa-null 293T cells and protein levels were measured. MEKK1 transfection dramatically increased the amount of C/EBPa (Figure 3d ; lane 4), an effect likely owing to JNK1 activation, as treatment of MEKK1-and C/EBPa-transfected cells with 20 mM JNK inhibitor SP600125 3 h post-transfection significantly reduced the amount of C/EBPa protein ( Figure 3d ; lane 5); SP600125 functions by directly inhibiting JNK (Han et al., 2001) .
We next confirmed that JNK affects C/EBPa at protein level rather than its mRNA by treating U937 cells with 50 mg/ml cycloheximide (a chemical which inhibits new protein synthesis in eucaryotes by inhibiting peptidyl transferase) before the addition of 50 ng/ml anisomycin for different time points as indicated. Immunoblot against C/EBPa after resolving RIPA lysates on SDS-PAGE shows that C/EBPa protein degradation is reduced when treated together with anisomycin ( Figure 3e ). However, slow degradation of C/EBPa after 0 h may be attributed to JNK activation by cycloheximide itself (Kyriakis and Avruch, 1990) . In addition, analysis of C/EBPa mRNA expression in anisomycin-induced and -uninduced U937 cells showed no increase in C/EBPa mRNA; rather was marginally downregulated (Supplementary Figure S1 ). Further, as JNK activation stabilizes C/EBPa protein expression, we determined if activation of JNK1 inhibits JNK-targeted C/EBPa ubiquitination. Therefore, we performed in vivo ubiquitination assay by transiently transfecting 293T cells with HA-tagged Ubiquitin (HAUbi) alone, together with C/EBPa, and with C/EBPa and MKK7, respectively. Twenty-four hours posttransfection, cells were harvested in RIPA buffer. Immunoblot against HA after immunoprecipitation of C/EBPa shows that C/EBPa is significantly ubiquitinated when co-transfected with HA-Ubi (Figure 3f ; lane 4), whereas this ubiquitination was inhibited in HA-Ubi-, C/EBPa-and MKK7-co-transfected cells where JNK1 is activated by MKK7 (Figure 3f; lane5) . MKK7 directly interacts with JNK1 and activates it by receiving signals from upstream kinases (Moriguchi et al., 1997) . Next, we demonstrate that inactive JNK indeed leads to enhanced C/EBPa ubiquitination; C/EBPa was co-transfected with varying amount of MKK7 (Figure 3g ; lanes 3, 4 and 5) and kinase-dead JNK mutant (HA-JNK*; Figure 3g ; lane 6) together with HA-Ubi; 24 h post-transfection, RIPA extract was prepared and separated on 10% SDS-PAGE. Immunoblot against HA antibody shows transfection of kinasedead JNK with C/EBPa was sufficient to enhance ubiquitination of later. Note that in a separate experiment, activation of mutant JNK by co-transfection of MKK7 could marginally inhibit C/EBPa ubiquitination (Supplementary Figure S2) .
Furthermore, if active JNK1 inhibits C/EBPa ubiquitination, it should enhance C/EBPa protein half-life. To answer this question, we performed pulse chase assay as described in Materials and methods. Autoradiogram developed after 2 days shows that C/EBPa protein halflife is prolonged (from 100 to B160 min) when induced with anisomycin as compared to uninduced cells ( Figure 3h) . Next, to investigate if phospho-JNK interacts in vivo with C/EBPa to protect later from ubiquitination, we performed co-immunoprecipitation of phospho-JNK from anisomycin-induced and -uninduced RIPA lysates. Immunoblot against C/EBPa and subsequent phospho-JNK antibody confirms in vivo interaction of phospho-JNK with C/EBPa (Figure 3i) . Alternatively, we also performed co-immunoprecipitation of C/EBPa, immunoblot with pJNK and later with C/EBPa after stripping the same membrane confirmed in vivo interaction of phsopho JNK and C/EBPa (Supplementary Figure S3) . Taken together, these data suggest that under normal conditions, JNK1 interaction with C/EBPa targets its ubiquitination which is inhibited upon interaction of phospho-JNK with C/EBPa in response to chemicals or stress. To our knowledge, this is first report of modulation of C/EBPa ubiquitination by JNK1.
JNK1 phosphorylates C/EBPa
The mechanisms that modulate ubiquitination by stress signals are: association with ancillary proteins, phosphorylation by specific kinases, and a combination of two (Fuchs et al., 1998) . JNK1 is a stress-regulated kinase and C/EBPa is known to be post-translationally modified by small ubiquitin-like modifier, ubiquitin and phosphorylation (Mahoney et al., 1992; Behre et al., 2002b; Subramanian et al., 2003; Ross et al., 1999 Ross et al., , 2004 . Therefore, we hypothesized, under stress conditions JNK1 physically associate, phosphorylates C/ EBPa and thereby inhibits its ubiquitination. To answer this, in vitro kinase assay performed using GST-C/EBPa as substrate and immunoprecipitated HA-JNK from transiently co-transfected 293T with MEKK1 as kinase shows JNK1 phosphorylates GST-C/EBPa (Figure 4a ; lane 1). Next, we assessed phosphomodification of immunopurified C/EBPa from mammalian cells. For this, we again performed in vitro kinase assay using immunoprecipitated C/EBPa from transiently transfected 293T as substrate and immunoprecipitated HA-JNK and kinase-dead HA-JNK (HA-JNK*) from transiently co-transfected 293T together with MEKK1 as kinase. Wild-type JNK phosphorylated C/EBPa (Figure 4b ; lane 3) whereas HA-JNK* could partially (Figure 4b ; lane 5). GST-c-Jun was used as positive control whereas pRK5 empty vector-transfected cells were used as control for JNK immunoprecipitation (lane 1). As JNK interacts with GST-DBD, we then examined if JNK1 can also phosphorylate GST-DBD. In vitro kinase assay using GST-DBD as substrate and immunoprecipitated HA-JNK and HA-JNK*, respectively as kinase from transiently co-transfected 293T with MEKK1 shows GST-DBD can be phosphorylated by JNK whereas there is little or no phosphorylation with mutant JNK (Figure 4c ). Collectively, these findings indicate that JNK1 does phosphorylate C/EBPa in DBD region. However, future work will be required to locate the amino-acid residue of C/EBPa being phosphomodified by JNK.
JNK1-induced increase in C/EBPa protein expression augments C/EBPa transactivation and DNA binding To assess if active JNK-induced increase in C/EBPa protein expression is also accompanied by an increase in C/EBPa transactivation activity, we transiently transfected 293T cells with a minimal thymidine kinase (TK) promoter containing two C/EBP sites cloned upstream of the luciferase reporter gene along with expression plasmids for hC/EBPa and MEKK1. Expression of the luciferase reporter gene was determined 24 h posttransfection. Transfection of MEKK1 expression construct significantly enhanced the ability of C/EBPa to transactivate a minimal C/EBP promoter almost fivefold, whereas this effect was drastically reduced to 1.5-fold when C/EBPa-and MEKK1-co-transfected cells were treated with 10 mM JNK inhibitor (SP600125) 3 h post-transfection. No significant change was observed in pTK-luc empty vector (Figure 5a ). Because JNK1 enhances C/EBPa protein expression and its transactivation capacity, we next asked, if MEKK1-mediated activation of JNK1 increases DNA-binding capacity of C/EBPa. To investigate this, 293T cells were transiently transfected with expression plasmids for hC/ EBPa and MEKK1 as indicated (Figure 5b) . NE was prepared 24 h post-transfection and 10 mg of NE was used in electrophoretic mobility shift assay (EMSA) reaction together with labelled probe which is a 30-nucleotide oligomer corresponding to the C/EBPabinding region on the granulocyte colony-stimulating factor (G-CSF) receptor promoter (Behre et al., 2002b ).
Significant increase in C/EBPa DNA binding with probe was observed when NE from co-transfection of C/EBPa and MEKK1 was used as compared to NE from C/ EBPa-transfected cells alone. Super shift with C/EBPa antibody was observed whereas no binding occurred when 50-fold excess of unlabelled probe was used as competitor. Figure 5c shows loading control for EMSA experiment. Taken together, these data suggest that active JNK-induced stabilization of C/EBPa protein indeed contributes to enhanced C/EBPa function. JNK1 is inactive and downregulated in certain AML subtypes In order to ascertain the correlation of C/EBPa and JNK1 interaction in myeloid cells, we assessed the JNK1 mRNA expression and its kinase activity in patients from different AML subtypes where C/EBPa is reported to be inactive. Affymetrix analysis shows that JNK1 mRNA expression is downregulated in AML patients as compared to the normal bone marrow mononuclear cells (Figure 6a ) from healthy volunteers. Total mRNA was isolated and processed as described before (Schoch et al., 2002) . Standard affymetrix software (Micro array Suite, Version 5.0) and the HG-U133A set of normalization controls were used for data analysis. As recommended by the manufacturer, 100 human maintenance genes served as a tool to normalize and scale the data before performing data comparisons. AML patient samples included French-American-British M2 patients with translocation t(8;21), normal karyotype, complex karyotype, M3 with t(15;17), M4eo inversion 16 (inv 16) and mixed lineage leukemia (MLL). As amount of mRNA expression of a gene does not always correspond to its protein expression and moreover our data suggests that active JNK is required for C/EBPa activity, we therefore analysed phospho-JNK protein expression. Patient samples (M2 with t(8;21), M3 with t(15;17), MLL and chronic myeloid leukemia (CML)) were lysed in RIPA buffer and 50 mg of protein was resolved on 8% SDS-PAGE. Immunoblot against pJNK antibody shows that pJNK expression (served as measure of JNK1 kinase activity Figure 6b ; upper panel) is decreased in these AML patients as compared to normal bone marrow mononuclear cells. Also, phospho-c-Jun expression (Figure 6b ; middle panel) was consistent with decreased JNK kinase activity as shown by re-blotting the same membrane. The same membrane was stripped and blotted with calreticulin as loading control. As expected, JNK kinase activity was increased in CML patients (Raitano et al., 1995) . These findings led us to hypothesize that physical interaction of active JNK with C/EBPa may positively regulate later whereas downregulation and/or inactivation of JNK may lead to C/EBPa inactivation as seen in AML.
Discussion
Protein-protein interactions operative at every biological step are important to the formation of complexes and signal transduction through protein pathways. Perturbation in such multiprotein complexes often leads to improper functioning as seen in leukemia. The molecular mechanism by which C/EBPa is regulated at protein level in normal stem cell development and AML is not fully elucidated. Therefore, we applied a mass spectrometry-based proteomic approach to identify interacting proteins of C/EBPa. The significance of our approach stems from the fact that we could identify JNK1, PAK6, MADP-1, ZNF45 and other proteins ( Figure 1f ) interacting with the DBD of C/EBP transcription factors. Furthermore, we show that JNK1 indeed interacts with full-length C/EBPa and modulates its activity via ubiquitination. JNK, a prompt stress-responsive kinase has been reported to regulate protein stability of its associated substrates. Several recent studies have shown the requirement of physical association of the stressresponsive factor JNK1 with other proteins in order to affect protein stability (Fuchs et al., 1996 (Fuchs et al., , 1997 . Our finding shows, like with other proteins, JNK does physically associate with C/EBPa in vivo and in vitro in co-immunoprecipitation and GST pull down, respectively; Note that JNK and phospho-JNK both interact with C/EBPa (Figure 2b and 3i) . We show that physical association of JNK with C/EBPa inhibits ubiquitination of C/EBPa. In vivo ubiquitination assay showed that, under normal conditions, JNK interaction with C/EBPa targets ubiquitination of C/EBPa presumably by attracting the enzymes of the ubiquitination machinery to C/EBPa, thereby marking it for proteasome-dependent degradation. However, in response to stress, that is, when phosphorylated active JNK interacts with C/ EBPa, this ubiquitination is inhibited (Figure 3f and g ). Our data are consistent with the findings that JNK regulates ubiquitination-dependent degradation of a different subset of substrates by acquiring a specific phosphorylation pattern that affects conformation, stability and transcriptional activation (Musti et al., 1997; Fuchs et al., 1998; Ronai, 2004) . JNK regulates C/EBPa protein stability is even more evident from upregulation of C/EBPa protein expression in different myeloid cell lines upon JNK activation (Figure 3a-d) . Additionally, amount of C/EBPa immunoprecipitated from anisomycin-induced U937RIPA lysates was more as compared to the uninduced cells (Figure 3g; lanes 7  and 8) . Moreover, MEKK1-induced JNK activation leading to C/EBPa protein stability was abrogated when these cells were treated with JNK inhibitor, which strengthens the fact that JNK does regulate C/EBPa protein stability (Figure 3d ). More recently, Yoon K et al. have shown that C/EBPa protein is upregulated up to 70-fold upon ultraviolet B (UVB) irradiation in keratinocytes which supports our finding, as UVB is a potent activator of JNK (Yoon and Smart, 2004) .
In addition to its function as a transcription factor, C/EBPa acts as tumor suppressor which inhibits cell proliferation via transcription-independent mechanism in which C/EBPa forms a complex with cdk2 and cdk4 preventing cyclin/cdk complex formation, E2F inhibition and cell cycle progression. In case of signaldependent transcription factors, it is apparent that changes in their half-life could have a significant impact on the activity of the corresponding target genes. Therefore, regulation of C/EBPa protein levels through an ubiquitin-proteasomal pathway would serve to control both the transcription-dependent and transcription-independent activities of C/EBPa (Shim and Smart, 2003) . Active JNK-induced increase in C/EBPa protein was accompanied by a significant increase in C/EBPa transactivation activity, which dramatically reduced with JNK inhibitor treatment suggesting JNK-specific C/EBPa activation (Figure 5a ). Additionally, we also observed an increase in DNA-binding capacity of C/EBPa in the presence of active JNK in EMSA (Figure 5b ). Taken together, our findings suggest that JNK is required for C/EBPa stability which has impact on its activity.
The fact that c-Jun is protected from ubiquitination after being phosphorylated by JNK (Fuchs et al., 1996; Musti et al., 1997) prompted us to investigate whether JNK apart from physically associating, also phosphorylates C/EBPa in order to inhibit its ubiquitination. In in vitro JNK kinase assay, we show that wild-type JNK does phosphorylate C/EBPa and GST-C/EBPa whereas kinase-dead JNK could partially phosphorylate (Figure 4) . However, further study is required to more fully determine the contribution of direct CEBPa phosphorylation in its stabilization and the amino-acid residues of C/EBPa being targeted by JNK. In any case, physical interaction of JNK with C/EBPa and phosphorylation of later led us to hypothesize that JNK inhibits C/EBPa ubiquitination by phosphorylating and presumably changing its conformation making it inaccessible to the ubiquitin ligase and ubiquitination machinery as such to target C/EBPa for degradation.
Affymetrix analysis of JNK1 mRNA using an indirect measure for JNK activity in AML subtypes where C/ EBPa function is impaired such as M2 with translocation t(8;21), M3 with t(15;17) and AML with inversion 16, shows reduced JNK1 mRNA expression in comparison with normal bone marrow mononuclear cells from healthy volunteers (Figure 6a ). Additionally, phospho-JNK protein expression (kinase activity) in these subtypes is also decreased (Figure 6b) . A function for JNK is implicated in cancer but the mechanism of JNK action is unclear. Although number of patient samples used for pJNK expression is very few to state if pJNK kinase activity in AML is downregulated in general. However, it gives a rough estimate that JNK kinase activity is decreased in certain AML patients. A followup study on the expression levels of pJNK and C/EBPa in large number of patients might give important insights into JNK-regulated C/EBPa expression.
In conclusion, we propose a hypothetical model (Figure 6c ) for the importance of physical interaction of JNK with C/EBPa. Targeting ubiquitination of C/ EBPa by JNK requires tight interaction with C/EBPa; whereas interaction with pJNK and subsequent C/EBPa phosphorylation at unidentified amino-acid residue by JNK inhibits its ubiquitination, probably owing to altered conformation of C/EBPa, which is likely to inhibit the ubiquitination machinery. This results in increased C/EBPa stability and availability which is reflected by enhanced DNA binding and transcriptional activity of C/EBPa. Moreover, downregulation of JNK mRNA and kinase activity in different AML subtypes implicates that JNK activity is required for C/EBPa activation in myeloid cells and that loss of JNKregulated C/EBPa expression may render it inactive.
Materials and methods
GST pull down
We used plasmid constructs in which full-length C/EBPa and region comprising amino acids 270-358 encoding the conserved DBD of C/EBPs are cloned in frame with the GST in pGEX bacterial expression vector. Fusion proteins were expressed in transformed DH5a E. coli bacterial strain after 0.5 mM IPTG induction at 371C for 2 h and subsequently purified using immobilized glutathione sepharose 4B beads (Amersham Biosciences, Germany) by lysing in NETN buffer as described before (Rangatia et al., 2002) . Following washing, purified fusion proteins were lysed in SDS sample buffer, separated on 12% SDS-PAGE and visualized by commassie blue staining. NE of U937 cells was prepared using lysis buffer A and C, respectively, as described before (Rangatia et al., 2002) . Equal amount of fusion proteins were incubated with 1 mg of NE (in NETN buffer) for 3 h at 41C on a rotating shaker. After GST pull down, protein-bound GST sepharose beads were washed three times in NETN buffer. In addition, S 35 -methionine-labelled ivt JNK1 was pulled down with GST fusion proteins as described before (Reddy et al., 2002) .
2D-gel electrophoresis and MALDI-TOF mass spectrometry GST and GST-DBD were incubated with NE of myelomonocytic U937 cells. Beads with their associated proteins from NE were lysed in urea lysis buffer (66% urea plus one, 1% DTE, 4% CHAPS, 2.5 mM ethylenediaminetetraacetic acid (EDTA) and 2.5 mM ethyleneglycoltetraacetate) for 1 h at room temperature. Lysed beads were passed through RNA quiashredder (Quiagen, Germany), and resulting supernatant was ultracentrifuged for 1 h at 50 000 r.p.m. at 221C to eliminate DNA and other cellular debris. In the first dimension, 350 ml of dissolved proteins were separated on 18 cm long immobiline dry strip in the pH range 3-10 (Amersham Biosciences, Germany) by IEF. The reduction and alkylation of separated proteins were carried out in urea buffer containing 2% DTE and 2.5% iodoacetamide. Proteins were then separated in the second dimension using 12% SDS-PAGE. 2D gels were silver stained to visualize the protein spots. After comparison of the two silver-stained gels, differentially appearing protein spots from GST-DBD gel were excised and digested with 200 ng Trypsin (Promega, Mannheim, Germany) in ammonium bicarbonate solution for 16 h. Digested peptides were eluted in 70% acetonitrile, lyophilized and resuspended in 5 ml of 0.1% trifluoacetic acid in 10% acetonitrile. The dissolved peptides were mixed in 1:1 ratio with 2,5-dihydroxybenzoic acid matrix solution and loaded on anchorChip target plate (Bruker Daltonics, Leipzig, Germany). Peptide mass fingerprint and peptide sequencing was performed by MALDI-TOF (Reflex III, Bruker) and confirmed by MALDI-TOF-TOF (AB4700, Applied Biosystems, Darmstadt, Germany) mass spectrometer, corresponding proteins were identified by MASCOT database search.
Cell culture, plasmids 293T, U937 and HL 60 cells were cultured as described previously (Reddy et al., 2002) . NB4 cells were maintained in Rosewell Park Memorial Institute medium (RPMI) supplemented with 20% fetal bovine serum (FBS), 2.5% pen-strep and 2.5% glutamine. K562C/EBPa-Er and K562Er cells were maintained in RPMI (without phenol red) supplemented with 10% charcoal treated FBS (Hyclone, Nu¨rtingen, Germany) and 2 mg/ml puromycin. HA-JNK and kinase-dead HA-JNK mutant were provided by Dr A Keiser, GST-c-Jun corresponding to 35 kDa (1-79 amino acids fused with GST) was bought from Cell Signalling technology (Beverly, MA, USA), whereas GST-c-Jun with 40 kDa molecular size was bacterially purified. pCDNA3-human C/EBPa is described previously (Pabst et al., 2001b) . BR3 harbors mutations in the basic region that prevent DNA binding (amino acids: 297R, 298K, 300R and 302K of C/EBPa mutated to glycine, threonine, glycine and aspargine, respectively); Leu1, 2-Val cannot dimerize or bind DNA because of mutation of two leucines to valine within the leucine zipper; and GZ is a variant in which the C/EBPa leucine zipper is replaced with the leucine zipper from a yeast protein, GCN4. GZ retains the ability to homodimerize, bind DNA, and activate transcription, but is not expected to interact with endogenous basic region leucine zipper (bZIP) proteins via the leucine zipper. C/EBP-DBD plasmid constructs were kindly provided by Dr Alan Friedman and is described elsewhere (Landschulz et al., 1989) . Plasmid construct HA-ubiquitin (pMT123HA-Ubi) was kind gift from Dr Dirk Bohmann.
Co-immunoprecipitation and in vitro kinase assay Co-immunoprecipitation assay was performed form RIPA lysate of U937 cells (RIPA: 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 5 mM EDTA and 50 mM Tris pH8.0) as described previously (Rangatia et al., 2002) . Immunoprecipitated proteins were heated at 561C for 90 min in 2 Â SDS loading buffer and then boiled at 951C for 5 min before separation on 8% SDS-PAGE. Proteins were immunoblotted with JNK1 and C/EBPa antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany), other antibodies used are HA (Roche Diagnostics, Manheim, Germany) and Phospho-JNK antibody (Cell Signalling Technologies, USA).
In vitro kinase assay was performed as described before (Zada et al., 2003) .
EMSA and reporter assays
For EMSA analysis, a double-stranded G-CSF receptor promoter oligonucleotide extending from bp À57 to À38 was used as a probe; OligoA (AAG GTG TTG CAA TCC CCA GC) and OligoB (GCT GGG GAT TGC AAC ACC TT) were annealed and labelled with g-[ 32 P]dATP (GE Health Care, Munich, Germany) using T4 polynucleotide kinase (Invitrogen, Karlsruhe, Germany). EMSA was performed by incubating 10 mg of NE with 1 ng of the radiolabelled probe in binding buffer (10 mM HEPES pH 7.9, 50 mM KCl, 2.5 mM MgCl 2 , 1 mM dithiothreitol and 10% glycerol) and 0.5 mg of poly (dI-dC) (Amersham Biosciences, Munich, Germany) for 30 min as described before (Behre et al., 2002b) . For reporter assays, 293T cells were transfected using LipofectAMINE Plus as described by the manufacturer (Invitrogen, Karlsruhe, Germany). Firefly luciferase activities from the constructs phC/EBPa, pTK, pCDNA3-MEKK1, p(C/EBP)2TK and Renilla luciferase activity from the internal control plasmid pRL-null were determined 24 h after the initiation of the transfection protocols as described previously (Behre et al., 2002b) , The reporter construct p(C/EBP)2TK contains two adjacent ATTGCGCAAT consensus C/EBPa-binding sites cloned into pTK81 luciferase, was kindly provided by Dr Alan Friedman and is described previously (Nordeen, 1988; Friedman, 1996) . Results are given as means 7s.e.m. of three independent experiments.
In vivo HA ubiquitination assay, pulse chases labelling and Western blotting For in vivo HA ubiquitination assay, 1 Â 10 6 293T cells were transiently transfected with different constructs as described. Twenty-four hours post-transfection, cells were lysed in RIPA buffer and C/EBPa was immunoprecipitated from 500 mg protein. For pulse chase labelling, 3 Â 10 5 /ml HL60 cells in 50 ml were plated in normal RPMI medium 1 day before the experiment. Next day cells were washed twice with phosphate-buffered saline and grown in 3 ml labelling medium (RPMI without methionine and cysteine, supplemented with 0.2% dialysed FBS) for 15 min with 200 mCi/ml methionine with constant shaking at 371C in water bath. The cells were then washed and chased for various time points with normal RPMI medium in the absence or presence of anisomycin. Cells were lysed and C/EBPa was immunoprecipitated from equal amount of lysates. The resulting precipitates were subjected to 10% SDS-PAGE, autoradiography and densitometry analysis. Western blotting was performed as described before (Rangatia et al., 2002) .
Patient samples and affymetrix: Patient samples were referred to the Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Hospital Grosshadern, for routine cytomorphologic and cytogenetic analyses. At the time each AML patient was diagnosed, mononuclear cells from the bone marrow aspirate with more than 90% blast cells were purified by Ficoll gradient separation. The percentage of blast cells within the bone marrow carrying the respective fusion genes as detected by fluorescence in situ hybridization ranged from 52 to 99% (median 90%). For Western blot analysis, the healthy bone marrow cells were purchased from stem cell technologies (Cell Systems biotechnology, Vertrieb Gmbh, St Katharinen, Germany). There was no correlation between the percentage of blast cells and the fusion gene transcript levels. Microarray analyses were performed as reported previously (Schoch et al., 2002) by use of the GeneChip System (Affymetrix U95Av2 and U133A microarrays, Santa Clara, CA, USA).
